Erasca (ERAS) Cash & Current Investments (2020 - 2026)
Erasca (ERAS) reported Cash & Current Investments of $243.8 million for Q1 2026, down 19.96% on a YoY basis from $304.6 million in Q1 2025, and down 11.7% quarter-over-quarter from $276.1 million in Q4 2025.
Erasca (ERAS) Cash & Current Investments (2020 - 2026) Analysis & Trends
Erasca has reported Cash & Current Investments for 7 years, with the latest figure at $243.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments fell 19.96% year-over-year to $243.8 million; the trailing twelve-month figure through Mar 2026 stood at $243.8 million (down 19.96% YoY), and the FY2025 full-year result was $276.1 million, down 7.45% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $243.8 million, down from $276.1 million in the prior quarter.
- The five-year high for Cash & Current Investments was $435.6 million in Q4 2022, with the low at $243.8 million in Q1 2026.
- Historically, Cash & Current Investments has averaged $330.9 million across 5 years, with a median of $312.3 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Current Investments surged 130.92% — and 2023, when it slipped 28.3%.
- Erasca's Cash & Current Investments stood at $435.6 million in 2022, then slipped by 28.3% to $312.3 million in 2023, then decreased by 4.5% to $298.3 million in 2024, then declined by 7.45% to $276.1 million in 2025, then retreated by 11.7% to $243.8 million in 2026.
- The last three Cash & Current Investments figures came in at $243.8 million (Q1 2026), $276.1 million (Q4 2025), and $288.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Erasca | 4.28 Bn | 4.03 Bn | - | 243.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 243.79 Mn |
| Dec 31, 2025 | 276.08 Mn |
| Sep 30, 2025 | 288.40 Mn |
| Jun 30, 2025 | 300.66 Mn |
| Mar 31, 2025 | 304.59 Mn |
| Dec 31, 2024 | 298.31 Mn |
| Sep 30, 2024 | 318.91 Mn |
| Jun 30, 2024 | 408.41 Mn |
| Mar 31, 2024 | 393.76 Mn |
| Dec 31, 2023 | 312.35 Mn |
| Sep 30, 2023 | 296.67 Mn |
| Jun 30, 2023 | 317.25 Mn |
| Mar 31, 2023 | 389.74 Mn |
| Dec 31, 2022 | 435.62 Mn |
| Sep 30, 2022 | 355.93 Mn |
| Jun 30, 2022 | 292.73 Mn |
| Mar 31, 2022 | 392.53 Mn |
| Dec 31, 2021 | 414.48 Mn |
| Sep 30, 2021 | 486.65 Mn |
| Jun 30, 2021 | 193.67 Mn |